Protocol Outlines for Parts 1 and 2 of the Prospective Endoscopy III Study for the Early Detection of Colorectal Cancer: Validation of a Concept Based on Blood Biomarkers

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

DOI

  • Louise Rasmussen, Department of Surgical Gastroenterology, Hvidovre Hospital, Hvidovre, Denmark. lras2905@gmail.com.
  • ,
  • Michael Wilhelmsen
  • ,
  • Ib Jarle Christensen
  • ,
  • Jens Andersen
  • ,
  • Lars Nannestad Jørgensen
  • ,
  • Morten Rasmussen
  • ,
  • Jakob W Hendel
  • ,
  • Mogens R Madsen
  • ,
  • Jesper Vilandt
  • ,
  • Thore Hillig
  • ,
  • Michael Klærke
  • ,
  • Anna-Marie Bloch Münster
  • ,
  • Lars M Andersen
  • ,
  • Berit Andersen
  • Nete Hornung
  • ,
  • Erland J Erlandsen
  • ,
  • Ali Khalid
  • Hans Jørgen Nielsen

BACKGROUND: Programs for population screening of colorectal cancer (CRC) have been implemented in several countries with fecal immunochemical testing (FIT) as the preferred platform. However, the major obstacle for a feces-based testing method is the limited compliance that reduces the clinical sensitivity for detection of participants with non-symptomatic CRC. Therefore, research approaches have been initiated to develop screening concepts based on biomarkers in blood. Preliminary results show that protein, genetic, epigenetic, and metabolomic components may be valuable in blood-based screening concepts, particularly when combinations of the various components appear to lead to significant improvements.

OBJECTIVES: The protocol described in this paper focuses on the validation of concepts based on biomarkers in blood in a major population screened by FIT.

METHODS: In Part 1, participants will be identified and included through the Danish CRC Screening Program comprising initial FIT and subsequent colonoscopy to those with a positive result. Blood samples will be collected from 8000 FIT-positive participants, who are offered subsequent colonoscopy. Findings and interventions at colonoscopy together with personal data including co-morbidity will be recorded. Blood samples and data will also be collected from 6000 arbitrarily chosen participants with negative FIT. In Part 2, blood samples and data will be collected from 30,000 FIT-negative participants three times within 4 years. The blood samples will be analyzed using various in-house and commercially available manual and automated analysis platforms.

RESULTS: We anticipate Part 1 to terminate late August 2016 and Part 2 to terminate late September 2022. The results from Parts 1 and 2 will be presented within 12 to 18 months from termination.

CONCLUSIONS: The purpose of this study is to improve the efficacy of identifying participants with neoplastic bowel lesions, to identify false negative participants, to identify participants at risk of interval neoplastic lesions, to improve the compliance in screening sessions, and to establish guidelines for out-patient follow-up of at-risk participants based on combinations of blood-based biomarkers.

OriginalsprogEngelsk
Artikelnummere182
TidsskriftJMIR research protocols
Vol/bind5
Nummer3
Antal sider8
ISSN1929-0748
DOI
StatusUdgivet - 13 sep. 2016

Se relationer på Aarhus Universitet Citationsformater

ID: 103012352